Overview

Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to learn about the safety and efficacy of pexacerfont in outpatients diagnosed with Generalized Anxiety Disorder
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Citalopram
Dexetimide